Home › Companies › FBRX

Forte Biosciences

FBRX Acquired Lead: Phase 2 5 Biotech Distilled articles ↓

Dermatology GI/Hepatology Protein

Most recent annual filing: 2026-03-15

Pipeline (3 active programs)

FB102

Protein Target: CD122, IL-15

Biotech Distilled coverage (5)

2026-07-28 UPDATE: Forte Biosciences (FBRX) - argenx Paid $77 a Share
2026-07-09 UPDATE: Forte Biosciences (FBRX) - The Canary Sang 🔒 Paid
2026-05-12 UPDATE: Forte Biosciences (FBRX) - Fast Track in Celiac, Vitiligo Readout “Shortly” 🔒 Paid
2026-04-27 UPDATE: Forte Biosciences (FBRX) - The Dilution Gap Just Closed (And argenx Showed Up) 🔒 Paid
2026-04-03 Forte Biosciences (FBRX) - Scientific Deep Dive for FB102 and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.